Blog - Diabetes News
Real-time CGM is in our DNA
Dexcom is a pioneer in continuous glucose monitoring (CGM). Since 1999, we have developed innovative technology that has transformed how people manage diabetes. Our products are part of people’s daily lives, empowering them to live confidently and feel more in control, free to pursue their dreams. Innovating with the times, in line with advances in other technologies, is in our DNA as a company.
When we launched our first sensor in 2004, iPhones didn’t exist. When we launched our first sensor that communicated directly to a smartphone, iPhones still had home screen buttons, Blackberry devices still worked, and TikTok was yet to be launched. Today, our portfolio of real-time CGM sensors reliably deliver accurate glucose readings direct to over 130 different smartphones††, as well as offering real-time readings displayed on a smartwatch†† or separate receiver‡‡, should our users prefer that option.
Since 1999, we’ve been able to show our users their glucose data accurately in real-time, helping to ease the burden of living with diabetes – glucose readings at your fingertips, with no fingerpricks*. We’ve built our sensors from the ground up, with both real-time technology and our end-users, in mind.
As technology gathers pace, we continue to innovate and find new options that ease the burden of diabetes for our existing and future customers. Today, people walk around with more computing power in their pocket than NASA had to land Apollo 11 on the moon, and how we utilise these advances in technology for the diabetes community is always at the forefront of our innovation.
In 2018, we brought the world the first CGM that truly delivered on the promise of this life-changing technology with the Dexcom G6. The Dexcom G6 was the first sensor to require no fingersticks* or scanning to retrieve your data, as well as being real-time, easy to apply and simple to use. In addition, Dexcom G6 offers connectivity with multiple pumps and digital health apps. Today, along with our G7 and Dexcom ONE sensor, the G6 remains a tried-and-true companion for many living with diabetes, especially those using AID systems.
As the creator of the world’s most connected CGM†, Dexcom is committed to providing users with choice and flexibility when it comes to how they view their glucose data and deliver insulin1-7. Dexcom CGM is integrated with the Tandem t:slim X2 and YpsoMed mylife YpsoPump insulin pumps; digital health apps including Glooko, nudg, Happy Bob and Sugarmate; and, most recently, lifestyle devices from Garmin.
Our real-time CGM portfolio has also been designed with our users’ care teams mind. We want to make sure our products are easy to start, simple to keep using, and fit seamlessly into a user’s life. For healthcare professionals, this means patients with lower A1C∞,8, patients who can get started on a sensor without training×, and (via Clarity) your patients’ glucose data is accessible via an easy-to-use clinic portal, supporting a more simplified clinic workflow.
It's fair to say that in the years that have followed our first rtCGM sensor, we have learned a lot about how this technology works, and what our users expect from us. From continuously adding to our connected systems and technology ecosystem to creating a smaller**, and more discrete, form factor, we are listening to what our customers want, and continuing to innovate.
If you are interested in experiencing the Dexcom difference for yourself, please click the link below to submit your details and Dexcom will be in touch to arrange your free Dexcom sensor sample.
References and Footnotes
† Data on file 2022.
†† Display devices sold separately. For a list of compatible smart devices, please visit www.dexcom.com/compatibility.
‡‡ A touch screen receiver can be acquired as an optional display device.
∞ Dexcom CGM use is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.*
× G7 User Guide. Your patients can get started on the Dexcom G7 on their own - no training required.
**G7 wearable is 60% smaller than the G6
1 Brown, S, et al. Diabetes Care. 2021;44(7):1630–1640.
2 Peacock S, et al. Diabetes Ther. 2023;14(5):839-855.
3 Boughton CK, et al. Lancet Healthy Longevity. 2022(3):E135–42.
4 Ware J, et al. N Engl J Med. 2022;386:209–19.
5 Sheng T, et al. American Association of Diabetes Educators (AADE) Emerging Science Poster, 2019.
6 Sheng T, et al. Diabetes 2020;69(Supplement_1):861–P. 7 Ringenberger K, et al. J Endocrine Soc. 2021;5(Supp 1):A32. 8 Beck, RW, et al. JAMA. 2017;317(4):371-378.
† Data on file 2022.
†† Display devices sold separately. For a list of compatible smart devices, please visit www.dexcom.com/compatibility.
‡‡ A touch screen receiver can be acquired as an optional display device.
∞ Dexcom CGM use is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.*
× G7 User Guide. Your patients can get started on the Dexcom G7 on their own - no training required.
**G7 wearable is 60% smaller than the G6
1 Brown, S, et al. Diabetes Care. 2021;44(7):1630–1640.
2 Peacock S, et al. Diabetes Ther. 2023;14(5):839-855.
3 Boughton CK, et al. Lancet Healthy Longevity. 2022(3):E135–42.
4 Ware J, et al. N Engl J Med. 2022;386:209–19.
5 Sheng T, et al. American Association of Diabetes Educators (AADE) Emerging Science Poster, 2019.
6 Sheng T, et al. Diabetes 2020;69(Supplement_1):861–P. 7 Ringenberger K, et al. J Endocrine Soc. 2021;5(Supp 1):A32. 8 Beck, RW, et al. JAMA. 2017;317(4):371-378.